---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268041"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:54:41.263792+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029

## Summary
- Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.
- Cash & investments $475.5M at Sept 30, 2025; runway expected into 2029.
- CLN-049 showed ~30% CRc in R/R AML; oral presentation at ASH 2025.
- CLN-978 initial SLE & RA safety/B-cell data expected H1 2026.
- Discontinued CLN-619 and CLN-617; partner Taiho plans NDA for zipalertinib by year-end.

## SEC filing metadata
- accession: 0001193125-25-268041
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/0001193125-25-268041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268041
- JSON: https://secwatch.observer/filing/0001193125-25-268041.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.